Your browser doesn't support javascript.
loading
Application of novel PACS-based informatics platform to identify imaging based predictors of CDKN2A allelic status in glioblastomas.
Tillmanns, Niklas; Lost, Jan; Tabor, Joanna; Vasandani, Sagar; Vetsa, Shaurey; Marianayagam, Neelan; Yalcin, Kanat; Erson-Omay, E Zeynep; von Reppert, Marc; Jekel, Leon; Merkaj, Sara; Ramakrishnan, Divya; Avesta, Arman; de Oliveira Santo, Irene Dixe; Jin, Lan; Huttner, Anita; Bousabarah, Khaled; Ikuta, Ichiro; Lin, MingDe; Aneja, Sanjay; Turowski, Bernd; Aboian, Mariam; Moliterno, Jennifer.
Afiliação
  • Tillmanns N; Brain Tumor Research Group, Department of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, PO Box 208042, New Haven, CT, 06520, USA.
  • Lost J; Department of Diagnostic and Interventional Radiology, Medical Faculty, University Dusseldorf, 40225, Dusseldorf, Germany.
  • Tabor J; Brain Tumor Research Group, Department of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, PO Box 208042, New Haven, CT, 06520, USA.
  • Vasandani S; Department of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.
  • Vetsa S; Department of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.
  • Marianayagam N; Department of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.
  • Yalcin K; Department of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.
  • Erson-Omay EZ; Department of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.
  • von Reppert M; Department of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.
  • Jekel L; Brain Tumor Research Group, Department of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, PO Box 208042, New Haven, CT, 06520, USA.
  • Merkaj S; Brain Tumor Research Group, Department of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, PO Box 208042, New Haven, CT, 06520, USA.
  • Ramakrishnan D; Brain Tumor Research Group, Department of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, PO Box 208042, New Haven, CT, 06520, USA.
  • Avesta A; Brain Tumor Research Group, Department of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, PO Box 208042, New Haven, CT, 06520, USA.
  • de Oliveira Santo ID; Department of Radiation Oncology, Yale School of Medicine, 333 Cedar Street, PO Box 208042, New Haven, CT, 06520, USA.
  • Jin L; Brain Tumor Research Group, Department of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, PO Box 208042, New Haven, CT, 06520, USA.
  • Huttner A; R&D, Sema4, 333 Ludlow Street, North Tower, 8th Floor, Stamford, CT, 06902, USA.
  • Bousabarah K; Department of Pathology, Yale School of Medicine, New Haven, CT, USA.
  • Ikuta I; Visage Imaging, GmbH., Lepsiusstraße 70, 12163, Berlin, Germany.
  • Lin M; Department of Radiology, Mayo Clinic Arizona, 5711 E Mayo Blvd, Phoenix, AZ, 85054, USA.
  • Aneja S; Brain Tumor Research Group, Department of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, PO Box 208042, New Haven, CT, 06520, USA.
  • Turowski B; Visage Imaging, Inc., 12625 High Bluff Dr, Suite 205, San Diego, CA, 92130, USA.
  • Aboian M; Department of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.
  • Moliterno J; Department of Diagnostic and Interventional Radiology, Medical Faculty, University Dusseldorf, 40225, Dusseldorf, Germany.
Sci Rep ; 13(1): 22942, 2023 12 22.
Article em En | MEDLINE | ID: mdl-38135704
ABSTRACT
Gliomas with CDKN2A mutations are known to have worse prognosis but imaging features of these gliomas are unknown. Our goal is to identify CDKN2A specific qualitative imaging biomarkers in glioblastomas using a new informatics workflow that enables rapid analysis of qualitative imaging features with Visually AcceSAble Rembrandtr Images (VASARI) for large datasets in PACS. Sixty nine patients undergoing GBM resection with CDKN2A status determined by whole-exome sequencing were included. GBMs on magnetic resonance images were automatically 3D segmented using deep learning algorithms incorporated within PACS. VASARI features were assessed using FHIR forms integrated within PACS. GBMs without CDKN2A alterations were significantly larger (64 vs. 30%, p = 0.007) compared to tumors with homozygous deletion (HOMDEL) and heterozygous loss (HETLOSS). Lesions larger than 8 cm were four times more likely to have no CDKN2A alteration (OR 4.3; 95% CI 1.5-12.1; p < 0.001). We developed a novel integrated PACS informatics platform for the assessment of GBM molecular subtypes and show that tumors with HOMDEL are more likely to have radiographic evidence of pial invasion and less likely to have deep white matter invasion or subependymal invasion. These imaging features may allow noninvasive identification of CDKN2A allele status.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Glioma Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Glioma Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article